Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. ten-percent owner Bayview Legacy, LLC reported an indirect sale of 100,000 common shares on October 1, 2026, at a weighted average sale price of $23.8239 per share; individual sale prices ranged from $23.43 to $24.23, inclusive. After the sale, Bayview Legacy reported indirect holdings of 8,129,071 shares. The sale was made under a Rule 10b5-1 trading plan adopted by manager K. Charles Janac on December 12, 2025.
Arteris, Inc. (AIP) common stock is subject to a proposed sale by Bayview Legacy, LLC, identified as a 10% stockholder: 300,000 shares with an aggregate market value of $7,092,000.00. Morgan Stanley Smith Barney LLC is named in the sale information.
The shares are listed as acquired through a private acquisition from the issuer or an affiliate on November 5, 2013. The notice reports 49,152,102 shares outstanding as of October 1, 2026, and lists prior three-month 10b5-1 sales for Bayview Legacy, LLC and K. Charles Janac.
Arteris, Inc. (AIP) reported that its Chief Operating Officer, Laurent R. Moll, sold a total of 9,219 shares of common stock on September 14, 2026 in open-market or private transactions. The sales were made under a Rule 10b5-1 trading plan adopted on March 12, 2026, with prices including a weighted average of $20.8409 for 9,119 shares and $21.75 for 100 shares.
Arteris, Inc. (AIP) reports that company officer Laurent Moll has filed a notice to sell 12,219 shares of common stock under Rule 144 through Morgan Stanley Smith Barney. The shares have an aggregate market value of $277,249.11 as of September 14, 2026.
The planned sale consists of 9,219 shares issuable from Restricted Stock Units dated July 1, 2026 and 3,000 shares from the Employee Stock Purchase Plan dated November 21, 2024. Moll previously sold 39,541 shares on June 16, 2026 and 5,599 shares on July 2, 2026.
Arteris, Inc. (symbol: AIP) is the issuer of record for a Form 4 filing submitted to the SEC. Sinha Saurabh reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. (AIP) reported that Chief Financial Officer Saurabh Sinha received a grant of 142,835 restricted stock units (RSUs) on September 8, 2026. Each RSU represents a contingent right to receive one share of common stock, and the grant was made at a stated price of $0.00 per unit.
According to the vesting terms, 25% of the RSUs will vest on September 8, 2027, with the remainder vesting pro rata by day on the first day of each of 12 consecutive quarters, aligned with fiscal quarterly vesting commencing January 1, 2028. The RSUs have no expiration date, and no Rule 10b5-1 trading plan is reported for this award.
Arteris, Inc. (AIP) filed an initial statement of beneficial ownership (Form 3) for Saurabh Sinha, who serves as Chief Financial Officer. The filing does not report any equity holdings or transactions in Arteris securities by the reporting person at this time.
Arteris, Inc. (AIP) reported that K. Charles Janac, its President, CEO and a more than ten percent owner, had an affiliated entity sell 100,000 shares of Common Stock on September 1, 2026 at a weighted average price of $20.7497 per share in a sale transaction.
The shares were sold by Bayview Legacy, LLC, an entity for which Janac serves as manager and is deemed to have voting and dispositive power. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025. After the sales, Bayview Legacy, LLC held 8,229,071 shares indirectly, Janac held 175,148 shares directly, and the Charles and Lydia Janac Trust held 56,252 shares indirectly.
Arteris, Inc. (AIP) had a significant shareholder, Bayview Legacy, LLC, report the sale of 100,000 shares of Common Stock on September 1, 2026. The weighted average sale price was $20.7497 per share, with individual trades between $20.465 and $21.410.
After this transaction, Bayview Legacy, LLC reported 8,229,071 shares of Arteris Common Stock held indirectly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by K. Charles Janac, as manager of Bayview Legacy, LLC, on December 12, 2025, and Janac is deemed to have voting and dispositive power over these shares.
Arteris, Inc. (AIP) reported that its VP and General Counsel, Paul L. Alpern, exercised 4,000 incentive stock options for Arteris common stock on September 1, 2026 at an exercise price of $0.56 per share, receiving 4,000 common shares. On the same date, he sold 4,000 common shares at a weighted average price of $20.7658 per share in multiple trades between $20.61 and $21.38. Following the option exercise, he continues to hold 49,000 incentive stock options expiring on October 23, 2029. The acquisitions and sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026.
Arteris, Inc. (AIP) director Wayne C. Cantwell reported several transactions. On August 28, 2026, he exercised 5,000 non-qualified stock options at $0.60 per share to acquire 5,000 shares of common stock, leaving 70,000 options outstanding. On September 1, 2026, he made a bona fide gift of 5,000 directly held shares to The Cantwell Living Trust, for which he serves as trustee; the trust then held 194,698 shares. An additional 38,761 shares are held indirectly through a Decathlon Capital Management 401(k) plan for his benefit.